Skip to main content

2 Result(s)

within Medicine & Public Health Remove this filter Oncology Remove this filter Philip Galebach Remove this filter

and

  1. No Access

    Article

    Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients

    Crizotinib is recommended as first-line therapy for ALK-positive non-small cell lung cancer (NSCLC), but within a year of treatment initiation many patients develop resistance. With the recent approval of second-...

    Edmond Bendaly, Anand A. Dalal, Kenneth Culver, Philip Galebach… in Advances in Therapy (2017)

  2. No Access

    Article

    Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study

    This study aimed to provide the first real-world description of the characteristics, treatments, dosing patterns, and early outcomes of patients with ALK-positive non-small cell lung cancer (NSCLC) who received c...

    Edmond Bendaly, Anand A. Dalal, Kenneth Culver, Philip Galebach… in Advances in Therapy (2017)